Conatus Pharmaceuticals Inc Forecasted to Earn Q1 2017 Earnings of ($0.23) Per Share (CNAT)

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) – Equities researchers at SunTrust Banks issued their Q1 2017 earnings estimates for Conatus Pharmaceuticals in a research report issued on Thursday. SunTrust Banks analyst J. Boris expects that the brokerage will post earnings of ($0.23) per share for the quarter. SunTrust Banks has a “Buy” rating and a $26.00 price objective on the stock. SunTrust Banks also issued estimates for Conatus Pharmaceuticals’ Q2 2017 earnings at ($0.26) EPS, FY2017 earnings at ($0.13) EPS, FY2018 earnings at $3.95 EPS, FY2019 earnings at $2.15 EPS, FY2020 earnings at $2.56 EPS and FY2021 earnings at $3.37 EPS.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings results on Wednesday, March 15th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.09. During the same quarter in the prior year, the firm posted ($0.30) earnings per share.

Your IP Address:

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Several other equities analysts have also recently issued reports on CNAT. Zacks Investment Research cut Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 22nd. HC Wainwright upped their price objective on Conatus Pharmaceuticals from $9.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, December 20th. Stifel Nicolaus upped their price objective on Conatus Pharmaceuticals from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, December 20th. Finally, FBR & Co set a $16.00 price objective on Conatus Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 20th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $13.25.

Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 4.73 on Monday. The stock has a 50 day moving average price of $4.77 and a 200 day moving average price of $3.16. Conatus Pharmaceuticals has a 12 month low of $1.45 and a 12 month high of $6.30. The stock’s market capitalization is $119.07 million.

Institutional investors have recently added to or reduced their stakes in the stock. ING Groep NV acquired a new position in Conatus Pharmaceuticals during the fourth quarter valued at about $110,000. Ellington Management Group LLC acquired a new position in Conatus Pharmaceuticals during the fourth quarter valued at about $154,000. Courage Capital Management LLC acquired a new position in Conatus Pharmaceuticals during the third quarter valued at about $200,000. United Capital Financial Advisers LLC boosted its position in Conatus Pharmaceuticals by 5.7% in the fourth quarter. United Capital Financial Advisers LLC now owns 154,578 shares of the biotechnology company’s stock valued at $815,000 after buying an additional 8,369 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Conatus Pharmaceuticals by 193.5% in the fourth quarter. Renaissance Technologies LLC now owns 183,700 shares of the biotechnology company’s stock valued at $968,000 after buying an additional 121,100 shares during the period. 15.90% of the stock is currently owned by institutional investors and hedge funds.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

5 Day Chart for NASDAQ:CNAT

Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply